158 related articles for article (PubMed ID: 33712343)
1. Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.
Shim KH; Kwon JE; Park SG; Choo SH; Kim SJ; Kim SI
Urol Oncol; 2021 May; 39(5):298.e13-298.e20. PubMed ID: 33712343
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
Sharma M; Yang Z; Miyamoto H
Medicine (Baltimore); 2019 Sep; 98(38):e17257. PubMed ID: 31567999
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
[TBL] [Abstract][Full Text] [Related]
5. Significance of nuclear factor - kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence.
Zupancic M; Pospihalj B; Cerovic S; Gazic B; Drev P; Hocevar M; Perhavec A
Radiol Oncol; 2020 Apr; 54(2):194-200. PubMed ID: 32324163
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
7. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
[TBL] [Abstract][Full Text] [Related]
8. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
10. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
11. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
12. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
13. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
14. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
Gevensleben H; Dietrich D; Golletz C; Steiner S; Jung M; Thiesler T; Majores M; Stein J; Uhl B; Müller S; Ellinger J; Stephan C; Jung K; Brossart P; Kristiansen G
Clin Cancer Res; 2016 Apr; 22(8):1969-77. PubMed ID: 26573597
[TBL] [Abstract][Full Text] [Related]
15. The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer.
He J; Yi M; Tan L; Huang J; Huang L
World J Surg Oncol; 2021 Jul; 19(1):215. PubMed ID: 34271938
[TBL] [Abstract][Full Text] [Related]
16. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
17. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
18. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
Baas W; Gershburg S; Dynda D; Delfino K; Robinson K; Nie D; Yearley JH; Alanee S
Clin Genitourin Cancer; 2017 Oct; 15(5):577-581. PubMed ID: 28461179
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]